Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2020-04-13 Purchase | 2020-04-13 5:19 pm | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 20,000 | $16 | $320,000 | 243,856 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-02-23 Option Award | 2024-02-23 5:07 pm | N/A 2034-02-22 | Keros Therapeutics Inc. | KROS | Seehra Jasbir CHIEF EXECUTIVE OFFICER | 125,000 | $0 | 125,000 (Direct) | View |
| 2024-02-13 Option Award | 2024-02-15 8:41 pm | N/A 2034-02-12 | Keros Therapeutics Inc. | KROS | Seehra Jasbir CHIEF EXECUTIVE OFFICER | 125,000 | $0 | 125,000 (Direct) | View |
| 2023-04-08 Exercise | 2023-04-11 4:05 pm | N/A 2029-06-18 | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 4,000 | $0 | 297,943 (Direct) | View |
| 2023-04-08 Exercise | 2023-04-11 4:05 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 4,000 | $0.48 | 297,943 (Direct) | View |
| 2023-02-16 Option Award | 2023-02-17 4:13 pm | N/A 2033-02-15 | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 200,000 | $0 | 200,000 (Direct) | View |
| 2022-06-15 Option Award | 2022-06-17 08:28 am | N/A 2032-06-15 | Eloxx Pharmaceuticals Inc. | ELOX | Seehra Jasbir Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2022-06-09 Exercise | 2022-06-10 4:12 pm | N/A 2028-03-25 | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 5,000 | $0 | 257,678 (Direct) | View |
| 2022-06-09 Exercise | 2022-06-10 4:12 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 5,000 | $0.3 | 257,678 (Direct) | View |
| 2022-01-21 Option Award | 2022-01-25 4:17 pm | N/A 2032-01-20 | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 165,000 | $0 | 165,000 (Direct) | View |
| 2021-05-19 Option Award | 2021-05-20 4:10 pm | N/A 2031-05-19 | Eloxx Pharmaceuticals Inc. | ELOX | Seehra Jasbir Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2021-01-10 Option Award | 2021-01-12 5:20 pm | N/A 2031-01-09 | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 127,200 | $0 | 127,200 (Direct) | View |
| 2020-05-20 Option Award | 2020-05-22 4:10 pm | N/A 2030-05-20 | Eloxx Pharmaceuticals Inc. | ELOX | Seehra Jasbir Director | 20,000 | $0 | 20,000 (Direct) | View |
| 2020-04-13 Conversion | 2020-04-13 5:19 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 11,169 | $0 | 243,856 (Direct) | View |
| 2020-04-07 Option Award | 2020-04-08 9:03 pm | N/A 2030-04-06 | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 696,569 | $0 | 696,569 (Direct) | View |
Ownership | 2020-04-07 7:39 pm | N/A N/A | Keros Therapeutics Inc. | KROS | Seehra Jasbir Chief Executive Officer | 0 | $0 | 588,576 (Direct) | View |